phrykt

LeonaBio, Inc. (LONA): who owns it and who trades it

As of Nov 16, 2026, LONA insiders reported 9 open-market sales worth $93.4K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark James Litton (CEO), with $45.5K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling LeonaBio

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LONA

44 funds and institutions reported LONA shares worth $70.4M at the end of Q2 2026, about 82% of the company. The largest holder is Perceptive Advisors LLC with 19.8%.

Funds and institutions (13F) 82%Everyone else 18%

10 largest owners, by share of the company

Perceptive Advisors LLC19.8%
Kalehua Capital Management LLC8.4%
ADAR1 Capital Management, LLC8.3%
Acorn Capital Advisors, LLC6.8%
NEA Management Company, LLC4.9%
Commodore Capital LP4.9%
TCG Crossover Management, LLC4.9%
Spruce Street Capital LP4.2%
Blackstone Inc.3.5%
Adage Capital Partners Gp, L.l.c.3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Perceptive Advisors LLC1.86M19.79%$17.1MNo change
Kalehua Capital Management LLC787,4028.38%$7.2MNo change
ADAR1 Capital Management, LLC777,1008.27%$7.1M+7%
Acorn Capital Advisors, LLC634,5396.76%$5.8MNo change
NEA Management Company, LLC464,3984.94%$4.3MNo change
Commodore Capital LP464,3984.94%$4.3MNo change
TCG Crossover Management, LLC464,3984.94%$4.3MNo change
Spruce Street Capital LP393,7014.19%$3.6MNo change
Blackstone Inc.324,6383.46%$3MNew
Adage Capital Partners Gp, L.l.c.300,0003.19%$2.8MNew
Vanguard Capital Management LLC275,2332.93%$2.5M+41%
Seven Fleet Capital Management LP154,1531.64%$1.4M-6%
Propel Bio Management, LLC149,2791.59%$1.4MNo change
Simplify Asset Management Inc.149,2791.59%$1.4MNo change
Geode Capital Management, LLC80,4180.86%$740K+0%
BlackRock, Inc.79,1860.84%$728K+41%
Renaissance Technologies LLC77,4240.82%$712K+21%
Vanguard Fiduciary Trust Co42,8140.46%$393K+7%
Bank of America Corp32,5570.35%$299KNo change
Millennium Management LLC32,4500.35%$298K+2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LONA insiders reported $0 of open-market purchases and $93.4K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$93.4K
9 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Mar 4, 2026
Filed Mar 5, 2026

Purchases and sales by month

$56.2K$56.2KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 4, 2026Mark James LittonCEOSale5,156$5.37$27.7KForm 4
Mar 4, 2026Robert RenningerCFOSale906$5.37$4.9KForm 4
Mar 4, 2026Mark WorthingtonGENERAL COUNSEL and CCOSale1,328$5.37$7.1KForm 4
Mar 4, 2026Kevin ChurchCHIEF SCIENTIFIC OFFICERSale1,359$5.37$7.3KForm 4
Mar 4, 2026Martin Javier SanCHIEF MEDICAL OFFICERSale1,720$5.37$9.2KForm 4
Jan 2, 2026Martin Javier SanCHIEF MEDICAL OFFICERSale1,644$6.88$11.3KForm 4
Jan 2, 2026Mark James LittonCEOSale2,586$6.88$17.8KForm 4
Jan 2, 2026Robert RenningerCFOSale297$6.88$2KForm 4
Jan 2, 2026Kevin ChurchCHIEF SCIENTIFIC OFFICERSale876$6.88$6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark James LittonPresident and CEO, Director–$45.5KMar 4, 2026
Martin Javier SanCHIEF MEDICAL OFFICER–$20.5KMar 4, 2026
Kevin ChurchCHIEF SCIENTIFIC OFFICER–$13.3KMar 4, 2026
Mark WorthingtonGENERAL COUNSEL and CCO–$7.1KMar 4, 2026
Robert RenningerChief Financial Officer–$6.9KMar 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LONA short interest

Low short interest. 0.8% of LONA shares are sold short: about 1 share in 126. Over the last 12 reports the number of shares short went up 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 74,491 LONA shares were sold short, 0.8% of the shares outstanding, down 14.7% from the report before. At the average daily volume of 65,795 shares, buying them all back would take about 1.1 trading days (days to cover).

Shares short, % of all shares

0.79%May 15Oct 301.04%

Days to cover

1.1May 15Oct 303.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202674,4910.79%-15%65,7951.1
Oct 15, 202687,3440.93%+356%726,4331.0
Sep 30, 202619,1660.20%-19%192,3211.0
Sep 15, 202623,6510.25%-41%64,6891.0
Aug 31, 202640,2930.43%+3%82,8131.0
Aug 14, 202638,9730.41%-4%11,1373.5
Jul 31, 202640,7140.43%-25%20,4842.0
Jul 15, 202653,9760.57%-4%57,2901.0
Jun 30, 202656,0700.60%+9%19,0363.0
Jun 15, 202651,6300.55%-9%17,5912.9
May 29, 202656,5920.60%-9%48,7801.2
May 15, 202661,9550.66%+7%37,4401.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

LeonaBio company events

LeonaBio filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 22, 2026.

  1. Sep 22, 2026AnnouncementIn December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock. Filing
  2. Aug 26, 2026AnnouncementLeonaBio, Inc. announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor, as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic… Filing
  3. Aug 14, 2026ResultsReleased financial results. Filing
  4. Jun 23, 2026VoteReported shareholder vote results. Filing
  5. May 7, 2026ResultsReleased financial results. Filing
  6. Mar 31, 2026DealAmended an earlier report. Of Form 8-K, (2) include additional information required by the Staff as a condition of the grant of the waiver, (3) add a copy of the Sermonix License as Exhibit 2.1, (4) update references to the registrant from Athira Pharma, Inc. (or Athira) to LeonaBio, Inc. (or LeonaBio) and (5) make minor… Filing
  7. Mar 26, 2026ResultsReleased financial results. Filing
  8. Mar 19, 2026LeadershipThe Company’s board of directors previously approved, subject to stockholder approval, the Company’s 2026 Equity Incentive Plan. Filing
  9. Jan 9, 2026LeadershipThe Company entered into an Amended and Restated Change in Control and Severance Agreement with Robert Renninger, the Company’s Chief Financial Officer. Filing
  10. Dec 18, 2025AgreementAmended an earlier report. Athira Pharma, Inc. entered into a securities purchase agreement with a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors, one of which is affiliated with a member of the board of directors of the Company… Filing
  11. Dec 18, 2025AgreementAthira Pharma, Inc. entered into a securities purchase agreement with a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors, one of which is affiliated with a member of the board of directors of the Company… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

LeonaBio financials

Famous investors that hold LONA

3 of the 50 well-known investors we track reported holding LONA in their latest 13F filing. The largest position is Ken Griffin's, worth $308K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202686,282$308K0.0%+763%
Jim Simons · Renaissance TechnologiesQ3 202656,966$203K0.0%-26%
Israel Englander · Millennium ManagementQ3 202628,620$102K0.0%-12%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named LONA in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Spruce Street Capital LP13G4.2%
Nov 13, 2026Spruce Street Capital LP13G4.2%
Nov 4, 2026Great Point Partners, LLC13G5.0%
Nov 4, 2026Great Point Partners, LLC13G5.0%
Oct 28, 2026Sermonix Pharmaceuticals, Inc.13D/A25.1%
Oct 28, 2026Sermonix Pharmaceuticals, Inc.13D/A25.1%
Oct 26, 2026Perceptive Advisors LLC13D/A20.0%
Oct 26, 2026Perceptive Advisors LLC13D/A20.0%

Questions about LeonaBio, Inc. (LONA) stock

Who owns the most LONA stock?

The largest reported owner of LeonaBio, Inc. (LONA) is Perceptive Advisors LLC, with 19.8% of the company. In total, 44 funds and institutions reported holding LONA at the end of Q2 2026, together about 82% of the shares. See the largest owners.

Are LONA insiders buying or selling?

In the last 12 months, LONA insiders reported no open-market purchases and 9 sales worth $93.4K. The latest trade was on Mar 4, 2026. See every trade.

What is the short interest in LONA?

As of Oct 30, 2026, 74,491 LONA shares were sold short, 0.8% of the shares outstanding, down 14.7% from the report before. At the average daily volume of 65,795 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.

Which famous investors hold LONA?

3 of the 50 well-known investors we track reported LONA in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $308K. See all holders.

Executive pay

LeonaBio's chief executive was paid a total of $1.4M for the year ended Dec 31, 2025, down 55% from $3.2M the year before. In the last 12 months, LeonaBio's executives and directors bought no stock on the open market and sold $93.4K.

Chief executive, total pay$1.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$771KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.